BCAL Diagnostics Limited

Equities

BDX

AU0000160921

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. 12:40:23 2024-04-29 am EDT 5-day change 1st Jan Change
0.092 AUD -3.16% Intraday chart for BCAL Diagnostics Limited -8.00% -7.07%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BCAL Diagnostics Appoints CEO MT
BCAL Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
BCAL Diagnostics Joins Forces to Conduct Breast Cancer Blood Test Study in India MT
BCAL Diagnostics Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Fall 5% MT
BCAL Diagnostics Files for Additional Australian Patent Application MT
BCAL Diagnostics Appoints COO MT
Bcal Diagnostics Limited Appoints Shane Ryan as Chief Operating Officer Effective 21 September 2023 CI
BCAL Diagnostics Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
9,246,318 Ordinary Options of BCAL Diagnostics Limited are subject to a Lock-Up Agreement Ending on 21-JUL-2023. CI
54,752,379 Ordinary Shares of BCAL Diagnostics Limited are subject to a Lock-Up Agreement Ending on 21-JUL-2023. CI
BCAL Diagnostics Appoints Advisor MT
Bcal Diagnostics Limited Opens New Laboratory in Sydney CI
BCAL Diagnostics Opens Laboratory in Sydney MT
BCAL Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
BCAL Diagnostics to Set Up Clinical Service Laboratory in Sydney MT
BCAL Diagnostics Limited Announces Establishment of Development & Clinical Service Laboratory CI
BCAL Diagnostics Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
BCAL Diagnostics Limited Enters US Product Development Agreement with Precion Inc CI
20,596,692 Ordinary Shares of BCAL Diagnostics Limited are subject to a Lock-Up Agreement Ending on 20-FEB-2022. CI
BCAL Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2021 CI
Bcal Diagnostics Limited Provides Additional Information on Recent Analysis to Distinguish Between Blood Samples of Breast Cancer Patients and Normal Control Samples CI
Bcal Diagnostics Limited Announces Recent Analysis Significantly Improves Commercial Prospects CI
BCAL Diagnostics Names New CEO MT
BCAL Diagnostics Limited Appoints John Hurrell as Chief Executive Officer, Effective 14 February 2022 CI
BCAL Diagnostics Limited Announces Strong Cohort 4 Testing Data Demonstrates Value of BCAL Test CI
Chart BCAL Diagnostics Limited
More charts
BCAL Diagnostics Limited is an Australia-based biotechnology company, which is focused on improving health outcomes for women. The Company’s principal activities include the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer, including preparation for clinical trials. It developed a blood screening test to be used alongside breast cancer screening methods. The technology initially complements imaging technologies, such as the mammogram, while it further progresses the development of a monitoring and screening test suitable for women of all ages and backgrounds in any location. Its BCAL test is a lipid biomarker blood (Breast Cancer Associated Lipids test) test with the potential to be used for breast cancer prevention, screening, and monitoring. The Company has partnered with Precion Inc. to optimize protocols and procedures for the clinical studies required for regulatory approvals across several jurisdictions.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. BDX Stock
  4. News BCAL Diagnostics Limited
  5. BCAL Diagnostics Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Fall 5%